参考文献/References:
[1] Ashina M, Terwindt GM, Al-Karagholi M, et al. Migraine: disease characterisation, biomarkers, and precision medicine[J]. Lancet, 2021, 397(1283): 1496-1504.
[2] Collaborators GN. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016[J]. The Lancet Neurology, 2019, 18(5): 459-480.
[3] Moskowitz MA, Reinhard JF Jr, Romero J, et al. Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine? [J]. Lancet, 1979, 2(8148): 883-885.
[4] Liu-Chen LY, Mayberg MR,Moskowitz MA. Immunohistochemical evidence for a substance P-containing trigeminovascular pathway to pial arteries in cats[J]. Brain Res, 1983, 268(1): 162-166.
[5] Mayberg MR, Zervas NT, Moskowitz M. Trigeminal projections to supratentorial pial and dural blood vessels in Cats demonstrated by horseradish peroxidase histochemistry[J]. J Comp Neurol, 1984, 223(1): 46-56.
[6] Keller JT, Saunders MC, Beduk A, et al. Innervation of the posterior fossa dura of the cat[J]. Brain Res Bull, 1985, 14(1): 97-102.
[7] Olesen J, Burstein R, Ashina M, et al. Origin of pain in migraine: evidence for peripheral sensitisation[J]. Lancet Neurol, 2009, 8(7): 679-690.
[8] Kosaras B, Jakubowski M, Kainz V, et al. Sensory innervation of the calvarial bones of the mouse[J]. J Comp Neurol, 2009, 515(3): 331-348.
[9] Uddman R, Edvinsson L, Ekman R, et al. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P[J]. Neurosci Lett, 1985, 62(1): 131-136.
[10] Davis KD, Dostrovsky JO. Responses of feline trigeminal spinal tract nucleus neurons to stimulation of the middle meningeal artery and sagittal sinus[J]. J Neurophysiol, 1988, 59(2): 648-666.
[11] Liu Y, Broman J, Edvinsson L. Central projections of sensory innervation of the rat superior sagittal sinus[J]. Neuroscience, 2004, 129(2): 431-437.
[12] Malick A, Strassman RM,Burstein R. Trigeminohypothalamic and reticulohypothalamic tract neurons in the upper cervical spinal cord and caudal medulla of the rat[J]. J Neurophysiol, 2000, 84(4): 2078-2112.
[13] Burstein R, Jakubowski M, Garcia-Nicas E, et al. Thalamic sensitization transforms localized pain into widespread allodynia[J]. Ann Neurol, 2010, 68(1): 81-91.
[14] Noseda R, Jakubowski M, Kainz V, et al. Cortical projections of functionally identified thalamic trigeminovascular neurons: implications for migraine headache and its associated symptoms[J]. J Neurosci, 2011, 31(40): 14204-14217.
[15] Moskowitz M. The neurobiology of vascular head pain[J]. Ann Neurol, 1984, 16(2): 157-168.
[16] Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory[J]. Brain, 1994, 117( Pt 1): 199-210.
[17] Karatas H, Erdener SE, Gursoy-Ozdemir Y, et al. Spreading depression triggers headache by activating neuronal Panx1 channels[J]. Science, 2013, 339(6123): 1092-1095.
[18] Zhang X, Levy D, Noseda R, et al. Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura[J]. J Neurosci, 2010, 30(26): 8807-8814.
[19] Zhang X, Levy D, Kainz V, et al. Activation of central trigeminovascular neurons by cortical spreading depression[J]. Ann Neurol, 2011, 69(5): 855-865.
[20] Moskowitz M A,Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches[J]. Cerebrovasc Brain Metab Rev, 1993, 5(期缺失): 159-177.
[21] Burstein R, Falkowsky O, Borsook D, et al. Distinct lateral and medial projections of the spinohypothalamic tract of the rat[J]. J Comp Neurol, 1996, 373(4): 549-574.
[22] Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia[J]. Ann Neurol, 2000, 47(5): 614-624.
[23] Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists[J]. Proc Natl Acad Sci USA, 2004, 101(12): 4274-4279.
[24] Deen M, Hougaard A, Hansen HD, et al. Association between sumatriptan treatment during a migraine attack and central 5-HT1B receptor binding[J]. JAMA Neurol, 2019, 76(7): 834-840.
[25] Burstein R, Zhang X, Levy D, et al. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains[J]. Cephalalgia, 2014, 34(11): 853-869.
[26] Melo-Carrillo A, Strassman AM, Nir RR, et al. Fremanezumab-A humanized monoclonal Anti-CGRP Antibody-Inhibits thinly myelinated(Aδ)but not unmyelinated(C)meningeal nociceptors[J]. J Neurosci, 2017, 37(44): 10587-10596.
[27] May A, Goadsby PJ. Substance P receptor antagonists in the therapy of migraine[J]. Expert Opin Investig Drugs, 2001, 10(4): 673-678.
[28] Rupniak N, Carlson E, Boyce S, et al. Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733,060 in gerbils[J]. Pain, 1996, 67(1): 189-195.
[29] Liu-Chen LY, Han DH,Moskowitz MA. Pia arachnoid contains substance P originating from trigeminal neurons[J]. Neuroscience, 1983, 9(4): 803-808.
[30] Liu-Chen LY, Gillespie SA, Norregaard TV, et al. Co-localization of retrogradely transported wheat germ agglutinin and the putative neurotransmitter substance P within trigeminal ganglion cells projecting to cat middle cerebral artery[J]. J Comp Neurol, 1984, 225(2): 187-192.
[31] Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine:studies characterizing cerebrovascular and neuropeptide changes seen in humans and Cats[J]. Ann Neurol, 1993(33): 48-56.
[32] Ashina H, Schytz HW, Ashina M. CGRP in human models of migraine[J]. Handb Exp Pharmacol, 2019, 255(1): 109-120.
[33] Mason RT, Peterfreund RA, Sawchenko PE, et al. Release of the predicted calcitonin gene-related peptide from cultured rat trigeminal ganglion cells[J]. Nature, 1984, 308(5960): 653-655.
[34] Ebersberger A, Averbeck B, Messlinger K, et al. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro[J]. Neuroscience, 1999, 89(3): 901-907.
[35] Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system[J]. Ann Neurol, 1988, 23(2): 193-196.
[36] Samsam M, Coveñas R, Ahangari R, et al. Simultaneous depletion of neurokinin A, substance P and calcitonin gene-related peptide from the caudal trigeminal nucleus of the rat during electrical stimulation of the trigeminal ganglion[J]. Pain, 2000, 84(2/3): 389-395.
[37] Schou WS, Ashina S, Amin FM, et al. Calcitonin gene-related peptide and pain: a systematic review[J]. J Headache Pain, 2017, 18(1): 34.
[38] Vollesen AL, Amin FM, Ashina M. Targeted pituitary adenylate Cyclase-Activating peptide therapies for migraine[J]. Neurotherapeutics, 2018, 15(2): 371-376.
[39] Miyata A, Jiang L, Dahl RD, et al. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues(PACAP38)[J]. Biochem Biophys Res Commun, 1990, 170(2): 643-648.
[40] Tajti J, Uddman R, Möller S, et al. Messenger molecules and receptor mRNA in the human trigeminal ganglion[J]. J Auton Nerv Syst, 1999, 76(2/3): 176-183.
[41] Uddman R, Tajti J, Möller S, et al. Neuronal messengers and peptide receptors in the human sphenopalatine and otic ganglia[J]. Brain Res, 1999, 826(2): 193-199.
[42] Uddman R, Tajti J, Hou M, et al. Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2[J]. Cephalalgia, 2002, 22(2): 112-116.
[43] Tuka B, Helyes Z, Markovics A, et al. Peripheral and central alterations of pituitary adenylate cyclase activating polypeptide-like immunoreactivity in the rat in response to activation of the trigeminovascular system[J]. Peptides, 2012, 33(2): 307-316.
[44] Zagami AS, Edvinsson L, Goadsby PJ. Pituitary adenylate cyclase activating polypeptide and migraine[J]. Ann Clin Transl Neurol, 2014(1): 1036-1040.
[45] Han X, Ran Y, Su M, et al. Chronic changes in pituitary adenylate cyclase-activating polypeptide and related receptors in response to repeated chemical dural stimulation in rats[J]. Mol Pain, 2017, 13(1):1744806917720361.
[46] Saito K, Markowitz S, Moskowitz M. Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches[J]. Ann Neurol, 1988, 24(6): 732-737.
[47] Buzzi MG, Carter WB, Shimizu T, et al. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion[J]. Neuropharmacology, 1991, 30(11): 1193-1200.
[48] Moskowitz M. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine[J]. Trends Pharmacol Sci, 1992, 13(8): 307-311.
[49] Van Den Broek RW, Maassenvandenbrink A, De Vries R, et al. Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels[J]. Eur J Pharmacol, 2000, 407(1/2): 165-173.
[50] Hou M, Kanje M, Longmore J, et al. 5-HT(1B)and 5-HT(1D)receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase[J]. Brain Res, 2001, 909(1/2): 112-120.
[51] Ramadan NM, Skljarevski V, Phebus LA, et al. 5-HT1F receptor agonists in acute migraine treatment: a hypothesis[J]. Cephalalgia, 2003, 23(8): 776-785.
[52] Beattie DT, Connor H. The influence of the trigeminal ganglion on carotid blood flow in anaesthetized guinea-pigs[J]. Br J Pharmacol, 1994, 112(1): 262-266.
[53] Eftekhari S, Salvatore CA, Jhansson S, et al. Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier[J]. Brain Res, 2015, 1600(1):93-109.
[54] Hay DL. CGRP Receptor Biology: Is There More Than One Receptor[J]. Handb Exp Pharmacol, 2019, 255(1):13-22.
[55] Levy D, Burstein R, Kainz V, et al. Mast cell degranulation activates a pain pathway underlying migraine headache[J]. Pain, 2007, 130(1/2): 166-176.
[56] Ohsawa M, Brailoiu GC, Shiraki M, et al. Modulation of nociceptive transmission by pituitary adenylate cyclase activating polypeptide in the spinal cord of the mouse[J]. Pain, 2002, 100(1/2): 27-34.
[57] Davis-Taber R, Baker S, Lehto SG, et al. Central pituitary adenylate cyclase 1 receptors modulate nociceptive behaviors in both inflammatory and neuropathic pain states[J]. The Journal of Pain, 2008, 9(5): 449-456.
[58] Akerman S, Goadsby P J. Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: Relevance to migraine[J]. Sci Transl Med, 2015, 7:308ra157.
[59] Waeber C, Moskowitz M. Migraine as an inflammatory disorder[J]. Neurology, 2005, 64(10 Suppl 2): S9-15.
[60] Lundberg JM, Brodin E, Hua X, et al. Vascular permeability changes and smooth muscle contraction in relation to capsaicin-sensitive substance P afferents in the guinea-pig[J]. Acta Physiol Scand, 1984, 120(2): 217-227.
[61] Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain[J]. J Neurosci, 1987, 7(12): 4129-4136.
[62] Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache[J]. Cephalalgia, 1988, 8(2): 83-91.
[63] Buzzi MG, Sakas D, Moskowitz M. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater[J]. Eur J Pharmacol, 1989, 165(2/3): 251-258.
[64] Buzzi MG, Moskowitz M. The antimigraine drug, sumatriptan(GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater[J]. Br J Pharmacol, 1990, 99(1): 202-206.
[65] Johnson KW, Schaus JM, Durkin MM, et al. 5-HT1F receptor agonists inhibit neurogenic dural inflammation in Guinea pigs[J]. Neuroreport, 1997, 8(9/10): 2237-2240.
[66] Louis SM, Jamieson A, Russell NJ, et al. The role of substance P and calcitonin gene-related peptide in neurogenic plasma extravasation and vasodilatation in the rat[J]. Neuroscience, 1989, 32(3): 581-586.
[67] Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine[J]. Ann Neurol, 1981, 9(4): 344-352.
[68] Hadjikhani N, Sanchez DM, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex[J]. Proc Natl Acad Sci U S A, 2001, 98(8): 4687-4692.
[69] Arngrim N, Hougaard A, Ahmadi K, et al. Heterogenous migraine aura symptoms correlate with visual cortex functional magnetic resonance imaging responses[J]. Ann Neurol, 2017, 82(6): 925-939.
[70] Schoonman GG, Van Der Grond J, Kortmann C, et al. Migraine headache is not associated with cerebral or meningeal vasodilatation--a 3T magnetic resonance angiography study[J]. Brain, 2008, 131(Pt 8): 2192-2200.
[71] Asghar MS, Hansen AE, Amin FM, et al. Evidence for a vascular factor in migraine[J]. Ann Neurol, 2011, 69(4): 635-645.
[72] Khan S, Amin FM, Christensen CE, et al. Meningeal contribution to migraine pain:a magnetic resonance angiography study[J]. Brain, 2019(142): 93-102.
[73] Amin FM, Asghar MS, Hougaard A, et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study[J]. Lancet Neurol, 2013, 12(5): 454-461.
[74] Bolay H, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model[J]. Nat Med, 2002(8): 136-142.
[75] Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks[J]. Nat Med, 1995, 1(7): 658-660.
[76] Afridi SK, Matharu MS, Lee L, et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate[J]. Brain, 2005, 128(Pt 4): 932-939.
[77] Stankewitz A, Aderjan D, Eippert F, et al. Trigeminal nociceptive transmission in migraineurs predicts migraine attacks[J]. Journal of Neuroscience, 2011, 31(6): 1937-1943.
[78] Maniyar FH, Sprenger T, Monteith TA, et al. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks[J]. Brain, 2014, 137(1): 232-241.
[79] Schulte LH, May A. The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks[J]. Brain, 2016, 139(7): 1987-1993.
[80] Ashina M, Hansen JM, Á DO, et al. Human models of migraine - short-term pain for long-term gain[J]. Nat Rev Neurol, 2017, 13(12): 713-724.
[81] Al-Karagholi MA, Hansen JM, Severinsen J, et al. The K(ATP)channel in migraine pathophysiology: a novel therapeutic target for migraine[J]. J Headache Pain, 2017, 18(1): 90.
[82] Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study[J]. Neurology, 2018, 91(24): e2222-e2232.
[83] Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine[J]. N Engl J Med, 2004, 350(11): 1104-1110.
[84] Ashina M. The most important advances in headache research in 2018[J]. Lancet Neurol, 2019, 18(1): 5-6.
[85] Miller S, Liu H, Warfvinge K, et al. Immunohistochemical localization of the calcitonin gene-related peptide binding site in the Primate trigeminovascular system using functional antagonist antibodies[J]. Neuroscience, 2016, 328(1): 165-183.(2022-01-03收稿)